Celltrion, Inc.
Research Celltrion, Inc. (068270) on Bullrun: market cap KRW 39.74T, dividend yield 0.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker068270
- ExchangeKS
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 39.74T
- Dividend yield0.4%
- Financial periodQ1 2026
- RevenueKRW 1.14T
- Net incomeKRW 346.14B
- Free cash flowKRW 135.82B
- Gross margin59.9%
Valuation Snapshot
latest market cap is KRW 39.74T; dividend yield is 0.4%.
About Celltrion, Inc.
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease;
Frequently asked questions
What is Celltrion, Inc.'s market cap?
Celltrion, Inc.'s market capitalization is KRW 39.74T.
Does Celltrion, Inc. pay a dividend?
Celltrion, Inc. has a dividend yield of 0.4%.
What does Celltrion, Inc. do?
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease;